Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)

Reuters02-26
Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)

Celldex reported a Q4 2025 net loss of USD 81.3 million and FY 2025 net loss of USD 258.8 million. Q4 2025 total revenue was USD 0.1 million and FY 2025 total revenue was USD 1.5 million. Q4 2025 R&D expenses were USD 75.3 million and G&A expenses were USD 11.9 million, while FY 2025 R&D expenses were USD 245.1 million and G&A expenses were USD 43.8 million. Cash, cash equivalents and marketable securities totaled USD 518.6 million as of Dec. 31, 2025, and Celldex said this is sufficient to fund current planned operations through 2027. On the business update, Celldex said enrollment was completed six months ahead of guidance in its Phase 3 chronic spontaneous urticaria (CSU) global registration studies (EMBARQ-CSU1 and EMBARQ-CSU2), with 1,939 patients enrolled; topline data are expected in Q4 2026 and a BLA submission is planned for 2027. The company also said its Phase 3 study in cold urticaria and symptomatic dermographism (EMBARQ-ColdU and -SD) is actively accruing, with Phase 2 data for barzolvolimab in CSU and ColdU/SD accepted for multiple presentations at the 2026 AAAAI Annual Meeting. Celldex added that enrollment is complete in Phase 2 studies of barzolvolimab in prurigo nodularis (topline data expected summer 2026) and atopic dermatitis (topline data expected late 2026), and that a Phase 1 proof-of-mechanism study of CDX-622 in asthma has been initiated, with additional Phase 1 multiple ascending dose and subcutaneous administration data anticipated in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602251601PRIMZONEFULLFEED9661088) on February 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment